Innate and adaptive immune responses in hepatitis B virus infection

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 126-132

  Das, Abhishek ^a   Maini, Mala K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Hepatitis B virus; Interferon; Natural killer T cells

Indexed keywords

ALPHA INTERFERON; BIM PROTEIN; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE HEPATITIS; ADAPTIVE IMMUNITY; CD8+ T LYMPHOCYTE; CELL DEATH; CHRONIC HEPATITIS; CYTOKINE PRODUCTION; DISEASE MODEL; EFFECTOR CELL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LIVER CELL; LIVER INJURY; LYMPHOCYTE FUNCTION; MICROARRAY ANALYSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ACUTE DISEASE; ADAPTIVE IMMUNITY; ANIMALS; CYTOKINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, INNATE; LIVER; T-LYMPHOCYTES;

EID: 77952576643     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000282075     Document Type: Review

References (53)

1. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
2. Lanier LL: Evolutionary struggles between NK cells and viruses. Nat Rev Immunol 2008;8:259-268.
3. Dalod M, Hamilton T, Salomon R, et al: Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. J Exp Med 2003;197:885-898.
4. Tough DF, Borrow P, Sprent J: Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996;272:1947-1950. (Pubitemid 26234507)
5. Wieland SF, Vega RG, Muller R, et al: Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol 2003;77:1227-1236.
6. Wieland SF, Guidotti LG, Chisari FV: Intra-hepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000;74:4165-4173.
7. McClary H, Koch R, Chisari FV, Guidotti LG: Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000;74:2255-2264.
8. Robek MD, Boyd BS, Chisari FV: Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005;79:3851-3854.
9. Sommereyns C, Paul S, Staeheli P, Michiels T: IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4:e1000017.
10. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV: Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000;192:921-930.
11. Wieland S, Thimme R, Purcell RH, Chisari FV: Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004;101:6669-6674.
12. Wieland SF, Chisari FV: Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 2005;79:9369-9380.
13. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV: Viral clearance without destruction ofinfected cells during acute HBV infection. Science 1999;284:825-829.
14. Webster GJ, Reignat S, Maini MK, et al: Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000;32:1117-1124.
15. Dunn C, Peppa D, Khanna P, et al: Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009;137:1289-1300.
16. Bertoletti A, Maini MK: Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Immunol 2000;12:403-408. (Pubitemid 30410344)
17. Penna A, Chisari F V, Bertoletti A, et al: Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991;174:1565-1570.
18. Bertoletti A, Ferrari C, Fiaccadori F, et al: HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 1991;88:10445-10449.
19. Maini MK, Boni C, Lee CK, et al: The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191:1269-1280.
20. Webster GJ, Reignat S, Brown D, et al: Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004;78:5707-5719.
21. Boni C, Fisicaro P, Valdatta C, et al: Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81:4215-4225.
22. Lopes AR, Kellam P, Das A, et al: Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest 2008;118:1835-1845.
23. O'Connor L, Strasser A, O'Reilly LA, et al: Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 1998;17:384-395.
24. Bouillet P, Metcalf D, Huang DC, et al: Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999;286:1735-1738.
25. Wojciechowski S, Jordan MB, Zhu Y, White J, Zajac AJ, Hildeman DA: Bim mediates apoptosis of CD127(lo) effector T cells and limits T cell memory. Eur J Immunol 2006;36:1694-1706.
26. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ: Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003;426:671-676.
27. Sandalova E, Wei CH, Masucci MG, Levitsky V: Regulation of expression of Bcl-2 protein family member Bim by T cell receptor triggering. Proc Natl Acad Sci USA 2004;101:3011-3016.
28. Sandalova E, Hislop AD, Levitsky V: T-cell receptor triggering differentially regulates Bim expression in human lymphocytes from healthy individuals and patients with infectious mononucleosis. Hum Immunol 2006;67:958-965.
29. Bertolino P, Trescol-Biemont MC, Rabourdin-Combe C: Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival. Eur J Immunol 1998;28:221-236.
30. Morimoto J, Tan X, Teague RM, Ohlen C, Greenberg PD: Induction of tolerance in CD8+ T cells to a transgenic autoantigen expressed in the liver does not require cross-presentation. J Immunol 2007;178:6849-6860.
31. Holz LE, Benseler V, Bowen DG, et al: Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death. Gastroenterology 2008;135:989-997.
32. Das A, Hoare M, Davies N, et al: Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 2008.
33. Norris S, Collins C, Doherty DG, et al: Resident human hepatic lymphocytes are pheno-typically different from circulating lymphocytes. J Hepatol 1998;28:84-90.
34. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G: HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci USA 2005;102:7239-7244.
35. Kakimi K, Lane TE, Wieland S, et al: Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001;194:1755-1766.
36. Dunn C, Brunetto M, Reynolds G, et al: Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007;204:667-680.
37. Krishnan S, Kiang JG, Fisher CU, et al: Increased caspase-3 expression and activity contribute to reduced CD3zeta expression in systemic lupus erythematosus T cells. J Immunol 2005;175:3417-3423.
38. Tsuzaka K, Fukuhara I, Setoyama Y, et al: TCR zeta mRNA with an alternatively spliced 3'-untranslated region detected in systemic lupus erythematosus patients leads to the down-regulation of TCR zeta and TCR/CD3 complex. J Immunol 2003;171:2496-2503.
39. Nakagomi H, Petersson M, Magnusson I, et al: Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Ca ncer Res 1993;53:5610-5612.
40. Trimble LA, Lieberman J: Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex. Blood 1998;91:585-594.
41. Trimble LA, Shankar P, Patterson M, Daily JP, Lieberman J: Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation. J Virol 2000;74:7320-7330.
42. Bronstein-Sitton N, Cohen-Da niel L, Vaknin I, et al: Sustained exposure to bacterial antigen induces interferon-gamma-dependent T cell receptor zeta down-regulation and impaired T cell function. Nat Immunol 2003;4:957-964.
43. Rodriguez PC, Zea AH, DeSalvo J, et al: L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 2003;171:1232-1239.
44. Ando K, Moriyama T, Guidotti LG, et al: Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993;178:1541-1554.
45. Moriyama T, Guilhot S, Klopchin K, et al: Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990;248:361-364.
46. Sitia G, Isogawa M, Iannacone M, Campbell IL, Chisari FV, Guidotti LG: MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest 2004;113:1158-1167.
47. Kafrouni MI, Brown GR, Thiele DL: Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms. J Immunol 2001;167:1566-1574.
48. Tay CH, Welsh RM: Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol 1997;71:267-275.
49. Balkow S, Kersten A, Tran TT, et al: Concerted action of the FasL/Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection. J Virol 2001;75:8781-8791.
50. Galle PR, Hofmann WJ, Walczak H, et al: Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995;182:1223-1230.
51. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682.
52. Sheridan JP, Marsters SA, Pitti RM, et al: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-821.
53. Zheng SJ, Wang P, Tsabary G, Chen YH: Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 2004;113:58-64.